Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for BOEUF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
March 31, 2026 92.25%
December 31, 2025 92.46%
September 30, 2025 92.88%
June 30, 2025 92.33%
March 31, 2025 92.59%
December 31, 2024 92.62%
September 30, 2024 92.90%
June 30, 2024 92.27%
March 31, 2024 92.61%
December 31, 2023 91.81%
September 30, 2023 92.15%
June 30, 2023 91.32%
March 31, 2023 90.47%
December 31, 2022 91.46%
September 30, 2022 90.79%
June 30, 2022 89.02%
March 31, 2022 90.50%
December 31, 2021 89.28%
September 30, 2021 88.97%
June 30, 2021 89.48%
March 31, 2021 88.62%
Date Value
December 31, 2020 89.81%
September 30, 2020 91.42%
June 30, 2020 86.70%
March 31, 2020 88.72%
December 31, 2019 88.93%
September 30, 2019 87.74%
June 30, 2019 86.48%
March 31, 2019 85.89%
December 31, 2018 85.03%
September 30, 2018 81.84%
June 30, 2018 87.41%
March 31, 2018 82.11%
December 31, 2017 83.31%
September 30, 2017 87.79%
June 30, 2017 87.21%
March 31, 2017 88.84%
December 31, 2016 87.79%
September 30, 2016 79.21%
June 30, 2016 86.08%
March 31, 2016 84.22%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
BioInvent International AB 0.00%
Hansa Biopharma AB 60.14%
BioArctic AB 95.53%
Swedish Orphan Biovitrum AB 66.20%
Diamyd Medical AB -21.04K%

Gross Profit Margin (Quarterly) Related Metrics